We have located links that may give you full text access.
The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
GARDASIL is a quadrivalent recombinant vaccine against the human papilloma virus (HPV), more specifically against types 6, 11, 16 and 18. We present our 10 cases of vaccinated patients, aged from 16 to 23, whose condition was followed for a period of 5 years after vaccination. Our study was part of the world program for investigating GARDASIL, which included 25,000 patients from 33 countries. The results showed that GARDASIL vaccination reduced precancerous cervical, vaginal and vulvar lesions, associated with HPV types 16 and 18, as well as condylomas associated with HPV types 6 and 11.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app